CNS Pharmaceuticals and Image Analysis Group Partner to Further the Development of Berubicin

HOUSTON, Sept. 24, 2020 /PRNewswire/ — CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today announced it has selected Image Analysis Group (“IAG”) as the image partner for its upcoming Berubicin clinical trials.

The release as fetched from its publisher. cnspharma.com ↗